Medscape

EML4-ALK as a Predictive Marker for Response to EGFR Therapy

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...
ascopubs.org

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer Clonal and subclonal mutations (variant allele frequency ≥5%) in ALK confer inferior prognosis for ...
ascopubs.org

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA

Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations The ideas and opinions expressed in this Data Supplement do not ...
Seeking Alpha

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...
The American Journal of Managed Care

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...
News Medical

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic ...